127 related articles for article (PubMed ID: 30664711)
21. [Detection of the 30 base pair deletion of Epstein-Barr virus latent membrane protein 1 in extranodal nasal type NK/T-cell lymphoma and its prognostic significance].
Zhao S; Liu WP; Wang XL; Zhang WY; Jiang W; Tang Y; Li GD
Zhonghua Bing Li Xue Za Zhi; 2005 Nov; 34(11):720-3. PubMed ID: 16536316
[TBL] [Abstract][Full Text] [Related]
22. Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma.
Kinoshita S; Ishida T; Ito A; Narita T; Masaki A; Suzuki S; Yoshida T; Ri M; Kusumoto S; Komatsu H; Shimizu N; Inagaki H; Kuroda T; Scholz A; Ueda R; Sanda T; Iida S
Haematologica; 2018 Dec; 103(12):2059-2068. PubMed ID: 30076184
[TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr virus oncoprotein LMP1 mediates survivin upregulation by p53 contributing to G1/S cell cycle progression in nasopharyngeal carcinoma.
Guo L; Tang M; Yang L; Xiao L; Bode AM; Li L; Dong Z; Cao Y
Int J Mol Med; 2012 Apr; 29(4):574-80. PubMed ID: 22266808
[TBL] [Abstract][Full Text] [Related]
24. Aberrant BCL10 nuclear expression in nasal NK/T-cell lymphoma.
Shen L; Liang AC; Lu L; Au WY; Wong KY; Tin PC; Chan KW; Ko KH; Chen YW; Beh SL; Shimizu N; Tsuchiyama J; Tang JC; Kwong YL; Liang RH; Srivastava G
Blood; 2003 Aug; 102(4):1553-4. PubMed ID: 12900354
[No Abstract] [Full Text] [Related]
25. Activation of sterol regulatory element-binding protein 1 (SREBP1)-mediated lipogenesis by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) promotes cell proliferation and progression of nasopharyngeal carcinoma.
Lo AK; Lung RW; Dawson CW; Young LS; Ko CW; Yeung WW; Kang W; To KF; Lo KW
J Pathol; 2018 Oct; 246(2):180-190. PubMed ID: 29968360
[TBL] [Abstract][Full Text] [Related]
26. Heat shock protein 90 inhibitors repress latent membrane protein 1 (LMP1) expression and proliferation of Epstein-Barr virus-positive natural killer cell lymphoma.
Murata T; Iwata S; Siddiquey MN; Kanazawa T; Goshima F; Kawashima D; Kimura H; Tsurumi T
PLoS One; 2013; 8(5):e63566. PubMed ID: 23658841
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway.
Chen Y; Tsai YH; Tseng SH
Surgery; 2013 Jan; 153(1):4-16. PubMed ID: 22703967
[TBL] [Abstract][Full Text] [Related]
28. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling.
Ng SB; Selvarajan V; Huang G; Zhou J; Feldman AL; Law M; Kwong YL; Shimizu N; Kagami Y; Aozasa K; Salto-Tellez M; Chng WJ
J Pathol; 2011 Mar; 223(4):496-510. PubMed ID: 21294123
[TBL] [Abstract][Full Text] [Related]
29. Clinical usefulness of serum EBV DNA levels of BamHI W and LMP1 for Nasal NK/T-cell lymphoma.
Ishii H; Ogino T; Berger C; Köchli-Schmitz N; Nagato T; Takahara M; Nadal D; Harabuchi Y
J Med Virol; 2007 May; 79(5):562-72. PubMed ID: 17385697
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma.
Shin DY; Kim A; Kang HJ; Park S; Kim DW; Lee SS
Cancer Lett; 2015 Aug; 364(2):89-97. PubMed ID: 25790907
[TBL] [Abstract][Full Text] [Related]
31. [Nasal natural killer/T-cell lymphoma genes].
Li JM; Liu WP
Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):308-10. PubMed ID: 16181557
[No Abstract] [Full Text] [Related]
32. Clinicopathological features of Epstein-Barr virus-associated nasal T/NK cell lymphomas in southern Japan.
Seki D; Ueno K; Kurono Y; Eizuru Y
Auris Nasus Larynx; 2001 Jan; 28(1):61-70. PubMed ID: 11137365
[TBL] [Abstract][Full Text] [Related]
33. [Survivin expression in midline T-cell lymphoma in relation to Epstin-Barr virus infection].
Ming M; Wang DB; Yi JH; Zou DD; Yao JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):815-8. PubMed ID: 16277849
[TBL] [Abstract][Full Text] [Related]
34. LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis.
Ma SD; Xu X; Plowshay J; Ranheim EA; Burlingham WJ; Jensen JL; Asimakopoulos F; Tang W; Gulley ML; Cesarman E; Gumperz JE; Kenney SC
J Clin Invest; 2015 Jan; 125(1):304-15. PubMed ID: 25485679
[TBL] [Abstract][Full Text] [Related]
35. Expression of Epstein-Barr virus-encoded proteins in extranodal NK/T-cell Lymphoma, nasal type (ENKL): differences in biologic and clinical behaviors of LMP1-positive and -negative ENKL.
Kanemitsu N; Isobe Y; Masuda A; Momose S; Higashi M; Tamaru J; Sugimoto K; Komatsu N
Clin Cancer Res; 2012 Apr; 18(8):2164-72. PubMed ID: 22371452
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
37. Survivin messenger RNA levels in Epstein-Barr virus-positive patients with leukemic low-grade B-cell lymphomas expressing the latent membrane protein 1: evidence of apoptotic function?
Diamantopoulos PT; Polonyfi K; Sofotasiou M; Mantzourani M; Galanopoulos A; Spanakis N; Papadopoulou V; Kalala F; Iliakis T; Zareifi DS; Kodandreopoulou E; Vassilakopoulos T; Angelopoulou M; Siakantaris M; Terpos E; Variami E; Kollia P; Vaiopoulos G; Pangalis G; Viniou NA
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):56-60. PubMed ID: 24262330
[TBL] [Abstract][Full Text] [Related]
38. Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases.
Bernasconi M; Ueda S; Krukowski P; Bornhauser BC; Ladell K; Dorner M; Sigrist JA; Campidelli C; Aslandogmus R; Alessi D; Berger C; Pileri SA; Speck RF; Nadal D
Int J Cancer; 2013 Nov; 133(10):2341-50. PubMed ID: 23640782
[TBL] [Abstract][Full Text] [Related]
39. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
40. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA
Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
